This review discusses the evidence in support of the use of raltegravir (Isentress®), an integrase strand transfer inhibitor (INSTI) that has increased treatment options for the management of both treatment-experienced adult patients with multidrug-resistant HIV-1 strains and treatment-naïve patients.
Download PDF